Commercial Credit Report for Samik Pharm Co Ltd

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Samik Pharm Co Ltd is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Samik Pharm Co Ltd
(Cheongcheon-dong) 13
Cheongan-ro, Bupyeong-gu
Phone: +82 325196061p:+82 325196061	INCHEON, 21301 South Korea	Ticker: 014950014950

Business Summary

Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The Company sells its products in domestic and overseas markets.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
3/31/2025	12/31/2024	-	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations

Subsidiaries

Business Name	Address	City	State/Province	Country
Hana Twenty Eight Special Purpose Acquisition Co	82, Uisadang-daero, Yeongdeungpo-gu	SEOUL		South Korea

General Information

Outstanding Shares:	9,171,413	(As of 10/27/2025)
Stock Exchange:	KDQ
Fax Number:	+82 29243749

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN